Title: Withdrawal of Immunomodulators After Co-treatment Does not Reduce Trough Level of Infliximab in Patients with Crohn's Disease
Authors: Drobne, David
Bossuyt, Peter
Breynaert, Christine
Cattaert, Tom
Vande Casteele, Niels
Compernolle, Griet
Jürgens, Matthias
Ferrante, Marc
Ballet, Vera
Wollants, Willem-Jan
Cleynen, Isabelle
Van Steen, Kristel
Gils, Ann
Rutgeerts, Paul
Vermeire, Severine
Van Assche, Gert # ×
Issue Date: Mar-2015
Publisher: W.B. Saunders for the American Gastroenterological Association
Series Title: Clinical Gastroenterology and Hepatology vol:13 issue:3 pages:514-521.e4
Article number: S1542-3565(14)01072-6
Abstract: The addition of immunomodulators increases the efficacy of maintenance therapy with infliximab, for up to 1 year, in patients with Crohn's disease who have not been previously treated with immunomodulators. However, there are questions about the effect of withdrawing immunomodulator therapy from these patients. We studied the effects of treatment with infliximab and immunomodulators (co-treatment) and then immunomodulator withdrawal on long-term outcomes of patients, as well as trough levels of infliximab and formation of anti-infliximab antibodies (ATI).
ISSN: 1542-3565
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Therapeutic and Diagnostic Antibodies (+)
Translational Research in GastroIntestinal Disorders
Department of Human Genetics - miscellaneous
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science